α-Tocopheryl succinate alters cell cycle distribution sensitising human osteosarcoma cells to methotrexate-induced apoptosis
Author(s)
Alleva, Renata
Benassi, Maria Serena
Pazzaglia, Laura
Tomasetti, Marco
Gellert, Nina
Borghi, Battista
Neuzil, Jiri
Picci, Piero
Griffith University Author(s)
Year published
2006
Metadata
Show full item recordAbstract
a-Tocopheryl succinate (a-TOS) exerts pleiotrophic responses in malignant cells leading to cell cycle arrest, differentiation and apoptosis. We tested the ability of a-TOS to induce apoptosis or cell cycle perturbation in three human osteosarcoma (OS) cell lines which differ in their pRB and p53 status. We found high levels of apoptosis in OS cells carrying wild-type p53 gene when exposed to a-TOS, while the mutant p53 cells were resistant. A S/G2 transition arrest was observed in two OS cell lines exposed to a-TOS, which sensitised them to methotrexate, an agent whose activity is cell cycle-dependent. We propose that a-TOS ...
View more >a-Tocopheryl succinate (a-TOS) exerts pleiotrophic responses in malignant cells leading to cell cycle arrest, differentiation and apoptosis. We tested the ability of a-TOS to induce apoptosis or cell cycle perturbation in three human osteosarcoma (OS) cell lines which differ in their pRB and p53 status. We found high levels of apoptosis in OS cells carrying wild-type p53 gene when exposed to a-TOS, while the mutant p53 cells were resistant. A S/G2 transition arrest was observed in two OS cell lines exposed to a-TOS, which sensitised them to methotrexate, an agent whose activity is cell cycle-dependent. We propose that a-TOS may be used as a drug or an adjuvant for treatment of osteosarcomas.
View less >
View more >a-Tocopheryl succinate (a-TOS) exerts pleiotrophic responses in malignant cells leading to cell cycle arrest, differentiation and apoptosis. We tested the ability of a-TOS to induce apoptosis or cell cycle perturbation in three human osteosarcoma (OS) cell lines which differ in their pRB and p53 status. We found high levels of apoptosis in OS cells carrying wild-type p53 gene when exposed to a-TOS, while the mutant p53 cells were resistant. A S/G2 transition arrest was observed in two OS cell lines exposed to a-TOS, which sensitised them to methotrexate, an agent whose activity is cell cycle-dependent. We propose that a-TOS may be used as a drug or an adjuvant for treatment of osteosarcomas.
View less >
Journal Title
Cancer Letters
Volume
232
Issue
2
Publisher URI
Copyright Statement
© 2006 Elsevier. Please refer to the journal's website for access to the definitive, published version.
Subject
Oncology and carcinogenesis
Cancer cell biology